Ozoralizumab
Modify Date: 2024-01-03 08:24:21
Ozoralizumab structure
|
Common Name | Ozoralizumab | ||
|---|---|---|---|---|
| CAS Number | 1167985-17-2 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OzoralizumabOzoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1]. |
| Name | Ozoralizumab |
|---|
| Description | Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Ozoralizumab (ATN-103; 0-1000 pM; 48 h) 在 L929 细胞细胞毒性试验中具有高 TNFα 中和效力，对人 TNFα 和猴 TNFα 的 KD 值分别为 20.2 pM 和 16.1 pM[1]。 |
| In Vivo | Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 人 TNF 转基因小鼠) 抑制关节炎并降低关节炎评分[1]。 Animal Model: Tg197 human TNF transgenic mice[1] Dosage: 1 mg/kg Administration: Subcutaneous injection Result: Reduced the mean histopathologic score in the Tg197 mice. Had ability to neutralize TNFα activity. |
| References |
| No Any Chemical & Physical Properties |